Sales of Basilea’s antifungal drug, Cresemba (isavuconazole), in the Asia Pacific region have triggered a milestone payment of $1.25m from the company’s licence partner Pfizer, management has reported. Global Cresemba sales were $324m in FY21, resulting in significant royalty and milestone payments to Basilea. In our view, the triggering of milestones in new regions (Asia Pacific) is encouraging for Cresemba’s future sales growth. Cresemba is approved in 68 countries and marketed in 57 and is a ....
20 Jun 2022
Basilea Pharmaceutica - Yet another milestone payment from Pfizer
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Basilea Pharmaceutica - Yet another milestone payment from Pfizer
Sales of Basilea’s antifungal drug, Cresemba (isavuconazole), in the Asia Pacific region have triggered a milestone payment of $1.25m from the company’s licence partner Pfizer, management has reported. Global Cresemba sales were $324m in FY21, resulting in significant royalty and milestone payments to Basilea. In our view, the triggering of milestones in new regions (Asia Pacific) is encouraging for Cresemba’s future sales growth. Cresemba is approved in 68 countries and marketed in 57 and is a ....